DSGN Stock Price, Design Therapeutics, . Quote, Chart

Market Summary

USD4.61-0.16

Market Closed

-3.35%

DSGN Stock Price

View Fullscreen

DSGN RSI Chart

DSGN Valuation

Market Cap

269.5M

Price/Earnings (Trailing)

-4.59

Price/Sales (Trailing)

1.2K

Price/Free Cashflow

-5

DSGN Price/Sales (Trailing)

DSGN Profitability

Return on Equity

-21.77%

Return on Assets

-21.05%

Free Cashflow Yield

-20.02%

DSGN Fundamentals

DSGN Revenue

Revenue (TTM)

226.0K

DSGN Earnings

Earnings (TTM)

-58.7M

Earnings Growth (Yr)

42.44%

Earnings Growth (Qtr)

6.22%

Breaking Down DSGN Revenue

52 Week Range

1.948.31

(Low)(High)

Last 7 days

30.4%

Last 30 days

27.6%

Last 90 days

105.2%

Trailing 12 Months

-28.6%

How does DSGN drawdown profile look like?

DSGN Financial Health

Current Ratio

38.61

DSGN Investor Care

Shares Dilution (1Y)

0.98%

Diluted EPS (TTM)

-1.05

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2020	0	0	0	226.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Design Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 25, 2024	berger heather a.	bought	4,865	3.7429	1,300	-
Mar 25, 2024	schmid john p.	bought	66,605	3.74	17,809	-
Mar 22, 2024	schmid john p.	bought	33,132	3.6187	9,156	-
Sep 29, 2023	lappe rodney w	bought	49,287	2.347	21,000	-
Aug 29, 2023	william arsani	bought	4,782,400	2.44	1,960,000	-
Aug 29, 2023	prasad deepa	bought	27,669	2.3058	12,000	-
Aug 28, 2023	william arsani	bought	591,250	2.15	275,000	-
Dec 20, 2022	george simeon	bought	325,432	8.1358	40,000	-
Dec 20, 2022	sr one capital fund i aggregator lp	bought	325,432	8.1358	40,000	-
Dec 20, 2022	siffert joao md	bought	52,762	8.375	6,300	president and ceo

Which funds bought or sold DSGN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 08, 2024	Russell Investments Group, Ltd.	added	131	12,433	17,373	-%
May 08, 2024	Bleakley Financial Group, LLC	new	-	46,325	46,325	-%
May 08, 2024	STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM	new	-	72,875	72,875	-%
May 07, 2024	SUSQUEHANNA INTERNATIONAL GROUP, LLP	reduced	-46.25	-10,109	45,265	-%
May 07, 2024	NEW YORK STATE COMMON RETIREMENT FUND	unchanged	-	3,000	8,000	-%
May 06, 2024	SG Americas Securities, LLC	reduced	-39.99	-4,000	46,000	-%
May 06, 2024	Candriam S.C.A.	sold off	-100	-596,277	-	-%
May 06, 2024	Quantbot Technologies LP	unchanged	-	2,353	6,871	-%
May 03, 2024	GSA CAPITAL PARTNERS LLP	added	199	680,000	872,000	0.07%
May 03, 2024	Glassman Wealth Services	sold off	-100	-776	-	-%

Are Funds Buying or Selling DSGN?

Are funds buying DSGN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own DSGN

No. of Funds

Unveiling Design Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	cormorant asset management, lp	0.00%	0	SC 13G/A
Feb 14, 2024	citadel advisors llc	3.2%	6	SC 13G/A
Jan 23, 2024	state street corp	1.24%	695,224	SC 13G/A
Nov 14, 2023	ra capital management, l.p.	0%	0	SC 13G/A
Sep 07, 2023	blackrock inc.	4.3%	2,394,544	SC 13G/A
Apr 03, 2023	citadel advisors llc	4.6%	6	SC 13G
Feb 14, 2023	citadel advisors llc	4.4%	6	SC 13G/A
Feb 14, 2023	cormorant asset management, lp	3.09%	1,729,689	SC 13G/A
Feb 08, 2023	state street corp	5.43%	3,037,460	SC 13G
Feb 03, 2023	blackrock inc.	6.3%	3,508,024	SC 13G

Recent SEC filings of Design Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
May 08, 2024	8-K	Current Report
May 08, 2024	10-Q	Quarterly Report
Apr 25, 2024	DEFA14A	DEFA14A
Apr 25, 2024	DEF 14A	DEF 14A
Apr 25, 2024	ARS	ARS
Mar 25, 2024	4	Insider Trading
Mar 25, 2024	4	Insider Trading
Mar 20, 2024	3	Insider Trading
Mar 19, 2024	S-8	Employee Benefits Plan
Mar 19, 2024	8-K	Current Report

Peers (Alternatives to Design Therapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	47.0B	6.8B	9.93%	-6.23%	-7.88	6.87	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.2B	2.0B	-2.86%	-28.22%	-57.69	9.56	75.20%	68.82%
BMRN	15.5B	2.5B	-8.14%	-14.08%	75.54	6.28	13.74%	186.89%
INCY	12.0B	3.8B	-3.24%	-16.29%	16.12	3.19	8.58%	129.81%
MID-CAP
BBIO	5.4B	107.9M	1.09%	107.81%	-9.83	48.09	54.84%	-28.31%
APLS	5.2B	524.1M	-22.77%	-53.41%	-12.37	9.85	394.93%	39.61%
AXSM	3.5B	251.0M	1.40%	-8.18%	-11.81	13.94	73.58%	-86.73%
ARWR	3.1B	240.7M	-5.68%	-38.85%	-6.52	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-16.31%	-29.84%	-1.5K	3.09	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	-0.76%	-10.51%	28.42	4.5	60.38%	-34.49%
NVAX	627.6M	996.6M	1.36%	-50.17%	-1.57	0.63	-26.66%	65.49%
CRBP	467.5M	881.7K	16.76%	369.92%	-13.85	481.06	-77.61%	33.36%
INO	260.8M	4.9M	-4.04%	14.81%	-1.93	53.59	-54.97%	51.71%
IBIO	6.4M	2.1M	-14.75%	74.53%	-0.24	2.14	-13.45%	66.37%

Design Therapeutics, Inc. News

Latest updates

Design Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)				(In Thousands)
Description	(%) Q/Q	2020Q4	2020Q3	2020Q2	2020Q1
Revenue	65.0%	33.00	20.00	31.00	142
Operating Expenses	62.0%	3,894	2,403	1,494	765
S&GA Expenses	142.5%	1,186	489	433	388
R&D Expenses	41.5%	2,708	1,914	1,061	377
Interest Expenses	-	6.00	-	-	18.00
Net Income	-66.2%	-3,855	-2,320	-1,442	-663

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet														(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Assets	-3.7%	279	290	300	312	325	341	355	368	379	391	400	405	412	37.00
Current Assets	-3.8%	274	285	295	306	319	335	348	362	374	385	395	405	412	36.00
Cash Equivalents	38.7%	29.00	21.00	28.00	27.00	29.00	27.00	43.00	120	287	299	358	371	401	2.00
Net PPE	1.6%	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	1.00	2.00	1.00	0.00	0.00	0.00
Liabilities	-22.8%	9.00	12.00	15.00	15.00	12.00	14.00	14.00	11.00	8.00	8.00	9.00	4.00	4.00	2.00
Current Liabilities	-26.3%	7.00	10.00	12.00	12.00	9.00	11.00	10.00	7.00	5.00	5.00	6.00	3.00	4.00	2.00
Shareholder's Equity	-2.9%	270	278	285	297	313	327	341	357	370	382	392	402	408	-
Retained Earnings	-6.3%	-188	-177	-165	-149	-130	-110	-93.40	-75.70	-60.72	-47.46	-36.39	-25.07	-17.44	-11.92
Additional Paid-In Capital	0.7%	458	455	452	449	445	441	438	435	432	430	428	427	425	0.00
Shares Outstanding	0.0%	56.00	56.00	56.00	56.00	56.00	56.00	56.00	56.00	56.00	55.00	43.00	55.00	-	-
Float	-	-	-	-	164	-	-	-	373	-	-	-	481	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																	(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1
Cashflow From Operations	2.8%	-12,439	-12,798	-14,534	-13,804	-17,424	-15,091	-13,899	-10,500	-11,827	-9,227	-8,164	-8,289	-3,697	-2,844	-1,859	-1,307	-2,659
Share Based Compensation	16.9%	3,184	2,724	3,219	3,719	3,426	3,076	2,872	2,617	2,360	1,556	1,243	1,243	647	421	15.00	10.00	4.00
Cashflow From Investing	271.1%	20,616	5,555	15,266	11,982	19,733	-1,056	-63,389	-156,956	414	-50,059	-5,042	-21,571	23,028	1,998	3,187	501	-39,247
Cashflow From Financing	-96.0%	20.00	501	13.00	-	-	130	151	-202	156	193	30.00	5.00	378,983	1.00	-	-	44,531

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

DSGN Income Statement

2024-03-31

Condensed Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development (including related party amounts of $224 and $259, respectively)	$ 9,801	$ 15,730
General and administrative (including related party amounts of $135, and $135, respectively)	4,599	5,921
Total operating expenses	14,400	21,651
Loss from operations	(14,400)	(21,651)
Other income, net	3,295	2,357
Net loss	$ (11,105)	$ (19,294)
Net loss per share, basic	$ (0.20)	$ (0.35)
Net loss per share, diluted	$ (0.20)	$ (0.35)
Weighted-average shares of common stock outstanding, basic	56,488,527	55,908,033
Weighted-average shares of common stock outstanding, diluted	56,488,527	55,908,033

DSGN Balance Sheet

2024-03-31

Condensed Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 29,397	$ 21,200
Investment securities	241,289	260,598
Prepaid expenses and other current assets	3,200	2,786
Total current assets	273,886	284,584
Property and equipment, net	1,718	1,691
Right-of-use asset, related party	2,762	2,938
Other assets	427	430
Total assets	278,793	289,643
Current liabilities:
Accounts payable	1,372	1,940
Accrued expenses and other current liabilities (including related party amounts of $736 and $716 respectively)	5,722	7,682
Total current liabilities	7,094	9,622
Operating lease liability, net, related party	2,142	2,334
Total liabilities	9,236	11,956
Commitments and contingencies (See Note 8)
Stockholders' equity:
Common stock, $0.0001 par value; 200,000,000 shares authorized at March 31, 2024 and December 31, 2023; 56,494,271 and 56,473,598 shares issued, and shares outstanding at March 31, 2024 and December 31, 2023, respectively	6	6
Additional paid-in capital	458,449	455,245
Accumulated deficit	(188,731)	(177,626)
Accumulated other comprehensive (loss) income	(167)	62
Total stockholders' equity	269,557	277,687
Total liabilities and stockholders' equity	$ 278,793	$ 289,643

About Design Therapeutics, Inc.

Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs. It is also developing GeneTAC product candidate portfolio for the treatment of other nucleotide repeat expansion-driven monogenic diseases, such as Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease, and spinobulbar muscular atrophy. The company was incorporated in 2017 and is headquartered in Carlsbad, California.

CEO	Mr. Pratik Shah Ph.D.
WEBSITE	designtx.com
INDUSTRY	Biotechnology
EMPLOYEES	68

Design Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Design Therapeutics, Inc.? What does DSGN stand for in stocks?

DSGN is the stock ticker symbol of Design Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Design Therapeutics, Inc. (DSGN)?

As of Thu May 09 2024, market cap of Design Therapeutics, Inc. is 269.48 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of DSGN stock?

You can check DSGN's fair value in chart for subscribers.

What is the fair value of DSGN stock?

You can check DSGN's fair value in chart for subscribers. The fair value of Design Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Design Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for DSGN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Design Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether DSGN is over valued or under valued. Whether Design Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Design Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for DSGN.

What is Design Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 09 2024, DSGN's PE ratio (Price to Earnings) is -4.59 and Price to Sales (PS) ratio is 1.17 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. DSGN PE ratio will change depending on the future growth rate expectations of investors.